Logo image of RAPT

RAPT THERAPEUTICS INC (RAPT) Stock Fundamental Analysis

NASDAQ:RAPT - Nasdaq - US75382E1091 - Common Stock - Currency: USD

9.99  -0.11 (-1.09%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RAPT. RAPT was compared to 551 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RAPT as it has an excellent financial health rating, but there are worries on the profitability. RAPT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RAPT has reported negative net income.
In the past year RAPT has reported a negative cash flow from operations.
In the past 5 years RAPT always reported negative net income.
In the past 5 years RAPT always reported negative operating cash flow.
RAPT Yearly Net Income VS EBIT VS OCF VS FCFRAPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

RAPT has a Return On Assets of -62.29%. This is comparable to the rest of the industry: RAPT outperforms 40.11% of its industry peers.
RAPT's Return On Equity of -65.88% is in line compared to the rest of the industry. RAPT outperforms 57.35% of its industry peers.
Industry RankSector Rank
ROA -62.29%
ROE -65.88%
ROIC N/A
ROA(3y)-50.99%
ROA(5y)-46.45%
ROE(3y)-60.69%
ROE(5y)-53.99%
ROIC(3y)N/A
ROIC(5y)N/A
RAPT Yearly ROA, ROE, ROICRAPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

RAPT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RAPT Yearly Profit, Operating, Gross MarginsRAPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

8

2. Health

2.1 Basic Checks

RAPT has more shares outstanding than it did 1 year ago.
RAPT has more shares outstanding than it did 5 years ago.
RAPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RAPT Yearly Shares OutstandingRAPT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
RAPT Yearly Total Debt VS Total AssetsRAPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

RAPT has an Altman-Z score of 4.07. This indicates that RAPT is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.07, RAPT is doing good in the industry, outperforming 74.77% of the companies in the same industry.
RAPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.07
ROIC/WACCN/A
WACCN/A
RAPT Yearly LT Debt VS Equity VS FCFRAPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

RAPT has a Current Ratio of 21.11. This indicates that RAPT is financially healthy and has no problem in meeting its short term obligations.
RAPT has a Current ratio of 21.11. This is amongst the best in the industry. RAPT outperforms 94.01% of its industry peers.
RAPT has a Quick Ratio of 21.11. This indicates that RAPT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of RAPT (21.11) is better than 94.01% of its industry peers.
Industry RankSector Rank
Current Ratio 21.11
Quick Ratio 21.11
RAPT Yearly Current Assets VS Current LiabilitesRAPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.82% over the past year.
EPS 1Y (TTM)21.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RAPT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.62% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y88.45%
EPS Next 2Y36.07%
EPS Next 3Y23.77%
EPS Next 5Y12.62%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RAPT Yearly Revenue VS EstimatesRAPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2027 2029 2030 2031 2032 100M 200M 300M 400M 500M
RAPT Yearly EPS VS EstimatesRAPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RAPT. In the last year negative earnings were reported.
Also next year RAPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RAPT Price Earnings VS Forward Price EarningsRAPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RAPT Per share dataRAPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 -15

4.3 Compensation for Growth

RAPT's earnings are expected to grow with 23.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.07%
EPS Next 3Y23.77%

More info and screens

0

5. Dividend

5.1 Amount

RAPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RAPT THERAPEUTICS INC

NASDAQ:RAPT (8/6/2025, 5:20:02 PM)

9.99

-0.11 (-1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners76.65%
Inst Owner Change-15.17%
Ins Owners0.42%
Ins Owner Change0%
Market Cap165.23M
Analysts74.55
Price Target25.25 (152.75%)
Short Float %N/A
Short Ratio1.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-79.27%
Min EPS beat(2)-200.44%
Max EPS beat(2)41.9%
EPS beat(4)3
Avg EPS beat(4)-34.23%
Min EPS beat(4)-200.44%
Max EPS beat(4)41.9%
EPS beat(8)6
Avg EPS beat(8)-14.2%
EPS beat(12)9
Avg EPS beat(12)-7.69%
EPS beat(16)13
Avg EPS beat(16)-4.66%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-17.5%
PT rev (3m)395%
EPS NQ rev (1m)-1.18%
EPS NQ rev (3m)-358.93%
EPS NY rev (1m)0%
EPS NY rev (3m)-371.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.93
P/tB 0.93
EV/EBITDA N/A
EPS(TTM)-19.2
EYN/A
EPS(NY)-3.69
Fwd EYN/A
FCF(TTM)-6.58
FCFYN/A
OCF(TTM)-6.57
OCFYN/A
SpS0
BVpS10.72
TBVpS10.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.29%
ROE -65.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.99%
ROA(5y)-46.45%
ROE(3y)-60.69%
ROE(5y)-53.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.8%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.11
Quick Ratio 21.11
Altman-Z 4.07
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)61.2%
Cap/Depr(5y)59.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.87%
EPS Next Y88.45%
EPS Next 2Y36.07%
EPS Next 3Y23.77%
EPS Next 5Y12.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.04%
EBIT Next 3Y-4.7%
EBIT Next 5YN/A
FCF growth 1Y-44.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-47.32%
OCF growth 3YN/A
OCF growth 5YN/A